Alpha-GPC and cognition
What 5 graded rows on alpha-gpc agree on for cognition, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Alpha-GPC page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Alpha-GPC page, with its PubMed record.
Your question
Alpha-GPC and cognition
5 rows · 866 peopleThey agree: all 5 rows found an improvement.
- BGrade B× 2
- CGrade C× 1
- DGrade D× 2
- Rows
- 5
- Trials
- 12
- People
- 866
- Pooled reviews may count some twice
What the rows share
From the rowsThe best-graded row, grade B, is a meta-analysis of 449 people (2023) and found an improvement.
The rows run from 20 to 449 people, published from 2003 to 2025: 1 pooled review and 4 single studies.
The rows
5 improved- BGrade BCognitive scores in adult-onset cognitive impairment, alone or added to donepezil · Improved
Meta-analysis, 8 studies · n 449 · 2023 · Adults with Alzheimer's disease, vascular or mixed dementia and other adult-onset cognitive impairment (7 RCTs and 1 cohort)
1,200 mg/day (with donepezil 10 mg/day in the add-on trials) · 90 to 720 days
Against placebo or other medicines (3 RCTs, 449 people), MMSE scores were 3.5 points higher (95% CI 0.36–6.63) with very high heterogeneity (I² 98%). Added to donepezil (4 RCTs, 350 people), cognition (MD 1.72), function and behaviour also improved more than donepezil alone.
- BGrade BCognitive scores in mild to moderate Alzheimer-type dementia · Improved
RCT · n 261 · 2003 · Adults aged 60–80 with mild to moderate Alzheimer-type dementia
400 mg three times daily (1,200 mg/day) · 180 days
ADAS-Cog, MMSE and global impression scores improved versus placebo at 90 and 180 days.
- CGrade CCognitive scores in mild cognitive impairment · Improved
RCT · n 100 · 2024 · Adults with mild cognitive impairment
600 mg/day · 12 weeks
ADAS-Cog improved by 2.34 points more than placebo; adverse events did not differ between groups.
- DGrade DCognitive scores in type 2 diabetes with mild cognitive decline · Improved
RCT · n 36 · 2025 · Older adults with type 2 diabetes and MMSE 25–28 (Korea)
1,200 mg/day · 12 months
MMSE was 1.4 points higher than placebo at 6 months (P=0.059, not significant) and 1.7 points higher at 12 months (P<0.001); SF-36 physical health was also better.
- DGrade DAttention test (Stroop) after one dose · Improved
Crossover RCT · n 20 · 2024 · Resistance-trained men
315 mg or 630 mg single dose · Single dose
Stroop scores improved more after both doses than after placebo 60 minutes after intake.